Volume 2.02 | Jan 21

Cord Blood News 2.02, January 21, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events


Study Details First Successful Use of Expanded Umbilical-Cord Blood Units to Treat Leukemia
Scientists describe the first use of a method to vastly expand the number of stem/progenitor cells from a unit of cord blood in the laboratory that were then infused into patients resulting in successful and rapid engraftment. [Fred Hutchinson Cancer Research Center, Seattle]

MethoCult® Express Video  
Learn about the benefits of MethoCult® Express
for cord blood samples

by STEMCELL Technologies


New Way to Generate Abundant Functional Blood Vessel Cells from Human Stem Cells Discovered
In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists have developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels. [Weill Cornell Medical College, New York]



Notch-Mediated Expansion of Human Cord Blood Progenitor Cells Capable of Rapid Myeloid Reconstitution
The development of a clinically relevant Notch-mediated ex vivo expansion system for human CD34+ cord blood progenitors results in a marked increase in the absolute number of stem/progenitor cells, including those capable of enhanced repopulation in the marrow of immunodeficient nonobese diabetic–severe combined immunodeficient mice. [Blood]

The AC133+CD38, but Not the Rhodamine-Low, Phenotype Tracks Long-Term Culture-Initiating Cells and SCID-Repopulating Cell Function in Human Cord Blood Ex Vivo Expansion Cultures
Using an expansion system previously shown to increase hematopoietic progenitors and SCID-repopulating cells, researchers demonstrated that the rhodamine-low phenotype was lost, whereas AC133 expression was retained throughout culture. [Blood]

Mimicking the Haematopoietic Niche Microenvironment Provides a Novel Strategy for Expansion of Haematopoietic and Megakaryocyte-Progenitor Cells from Cord Blood
Researchers propose a novel strategy to expand these rare cells ex vivo, from a small portion of the cord blood unit, using fibronectin, a major component of hematopoietic niches, combined with cytokines, including thrombopoietin and the hematopoietic stress-associated acetylcholinesterase readthrough peptide. [Brit J Haematol]

Effective Generation of iPS Cells from CD34+ Cord Blood Cells by Inhibition of p53
The aim of this work was to determine the reprogramming methods, culture conditions, and cell fractions that can be used to generate induced pluripotent stem (iPS) cells from cord blood cells effectively. [Exp Hematol]

Substance P and Calcitonin Gene-Related Neuropeptides as Novel Growth Factors for Ex Vivo Expansion of Cord Blood CD34+ Hematopoietic Stem Cells
Researchers aimed to explore a novel approach for expansion, using Substance P and calcitonin gene-related peptide neuropeptides. [Growth Factors]

Hematopoietic Stem Cell Transplantation for Familial Hemophagocytic Lymphohistiocytosis and Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Japan
Post-stem cell transplantation outcomes of hemophagocytic lymphohistiocytosis patients were analyzed in Japan where Epstein-Barr virus-associated severe forms are problematic. [Pediatr Blood Cancer]

The Prognostic Value of Cord Blood Analysis in Erythropoietic Protoporphyria: the ‘Duesseldorf Cord Blood Study’

The aim of the study was to question the predictive value of cord blood analysis in newborn relatives of erythropoietic protoporphyria (EPP) patients as this may offer the earliest possible diagnosis of EPP in newborn relatives of affected patients. [Photodermatol Photo]

STEMSOFT Software Inc  
Designed for Cell Therapy. Used in Cell Therapy.


University Hospital Joins Statewide Cord Blood Collection Network
The Texas Cord Blood Bank launched a new partnership with University Health System to begin collecting life-saving umbilical cord blood at University Hospital. [San Antonio Business Journal]

European Medicines Agency Waives Requirement to Test StemEx® in Paediatric Patients 17 Years of Age and Under
The Gamida Cell-Teva Joint Venture announced that the Paediatric Committee of the EMA has granted product specific waivers for StemEx for all subsets of the paediatric population (birth to 17 years of age) in all conditions. [Gamida Cell Ltd. Press Release]

Cerus Corporation Reports Positive Outcome in European Study of 7-Day INTERCEPT Platelets
Cerus Corporation announced that INTERCEPT-treated platelet components were found to be effective for patient support following extended six and seven day storage in a clinical study conducted at four sites in Europe. [Cerus Corporation Press Release]

Cord Blood America Contracts with Center for Stem Cell Awareness to Sell Collection and Storage Services in Florida
Cord Blood America, Inc. announced that it has contracted with The Center for Stem Cell Awareness to re-sell its stem cell collection and storage services. [Cord Blood America, Inc. Press Release]

Hard to Treat Diseases Inc. Stem Cell Developments
Hard to Treat Diseases and its operating subsidiary Slavica BioChem want to point the shareholders back to the press release from Oct 29, 2009, where the company announced news about a possible merger with a European based, stem cell research company. [Hard to Treat Diseases Press Release]

Learn more about Cord Blood News: Archives  |  Events  |  Subscribe  |  Contact Us